Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2024

Conditions
Acute Decompensated Heart Failure (ADHF)Cardiorenal Syndrome (CRS)
Interventions
DRUG

Levosimendan

"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~•Levosimendan: loading dose 6-12 microgram/ kg then continuous infusion of 0.05-0.2 µg/kg/min."

DRUG

Dobutamine

"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~• Dobutamine: continuous infusion starting at 2.5 µg/kg/min, titrated up to 20 µg/kg/min as needed."

DRUG

Milrinone

"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~• Milrinone: 50 mcg/kg loading dose, then 0.375-0.75 mcg/kg/min IV according to patient response."

Trial Locations (1)

Unknown

faculty of medicine Ain shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER